Evidence map›Paper›PMID 24460101›Full record

ArticleBiomacromolecules2014

Toroidal-spiral particles for codelivery of anti-VEGFR-2 antibody and irinotecan: a potential implant to hinder recurrence of glioblastoma multiforme.

Vishal Sharma, Melanie Köllmer, Magdalena Szymusiak, Ludwig C Nitsche, Richard A Gemeinhart, Ying Liu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomacromolecules, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 13 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Vishal SharmaDepartment of Chemical Engineering and §Department of Bioengineering, University of Illinois at Chicago , Chicago, Illinois 60607, United States.
Melanie Köllmer
Magdalena Szymusiak
Ludwig C Nitsche
Richard A Gemeinhart
Ying Liu
University of Illinois Chicago · USUniversity of Illinois Urbana-Champaign · US

Funding

Center for Clinical and Translational ScienceUL1TR000050 · NCATS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI AZAR, DIMITRI T, MERMELSTEIN, ROBIN J. · 2012 to 2014
$9.8M
Understanding and Preventing Tumor Disperal with Hydrogel TherapeuticsR01NS055095 · NINDS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI GEMEINHART, RICHARD A · 2007 to 2011
$1.7M
EXTRAMURAL RESEARCH FACILITIES CONSTRUCTIONC06RR015482 · NCRR · UNIVERSITY OF ILLINOIS AT CHICAGO · PI BAUMAN, JERRY L · 2000 to 2000
$909k
NCATS NIH HHS UL1 TR000050NCRR NIH HHS C06 RR015482NCRR NIH HHS RR15482NINDS NIH HHS NS055095NINDS NIH HHS R01 NS055095
6 · The paper itself

Abstract

Heterogeneous toroidal-spiral particles (TSPs) were generated by polymer droplet sedimentation, interaction, and cross-linking. TSPs provide a platform for encapsulation and release of multiple compounds of different sizes and physicochemical properties. As a model system, we demonstrate the encapsulation and independently controlled release of an anti-VEGFR-2 antibody and irinotecan for the treatment of glioblastoma multiforme. The anti-VEGFR-2 antibody was released from the TS channels and its binding to HUVECs was confirmed by confocal microscopy and flow cytometry, suggesting active antibody encapsulation and release. Irinotecan, a small molecule drug, was released from the dense polymer matrix of poly(ethylene glycol) diacrylate (MW ~ 700 g/mol; PEGDA 700). Released irinotecan inhibited the proliferation of U251 malignant glioma cells. Since the therapeutic compounds are released through different pathways, specifically diffusion through the polymer matrix versus TS channels, the release rate can be controlled independently through the design of the structure and material of particle components.

Indexed as

Drug Delivery SystemsAntibodies, Anti-IdiotypicCamptothecinGlioblastomaHumansHuman Umbilical Vein Endothelial CellsIrinotecanParticle SizePolymersVascular Endothelial Growth Factor Receptor-2Antibodies, Anti-IdiotypicCamptothecinIrinotecanKDR protein, humanPolymersVascular Endothelial Growth Factor Receptor-2

Identifiers

PMID24460101
PMCPMC3983134
OpenAlexW1992145531

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.